12/5
04:27 pm
slgl
Sol-Gel Technologies (NASDAQ:SLGL) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Sol-Gel Technologies (NASDAQ:SLGL) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
11/29
03:38 pm
slgl
Sol-Gel Technologies (NASDAQ:SLGL) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Sol-Gel Technologies (NASDAQ:SLGL) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
11/20
07:30 am
slgl
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Low
Report
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
11/10
09:01 am
slgl
Insiders At Sol-Gel Technologies See Good Returns After Buying Stock Worth US$867.1k [Yahoo! Finance]
Low
Report
Insiders At Sol-Gel Technologies See Good Returns After Buying Stock Worth US$867.1k [Yahoo! Finance]
11/1
01:05 am
slgl
Sol-Gel Technologies (NASDAQ:SLGL) was downgraded by analysts at
Wall St
Low
Report
Sol-Gel Technologies (NASDAQ:SLGL) was downgraded by analysts at
Wall St
10/30
10:48 am
slgl
Sol-Gel Technologies (NASDAQ:SLGL) was upgraded by analysts at Zacks Research to a "hold" rating.
Low
Report
Sol-Gel Technologies (NASDAQ:SLGL) was upgraded by analysts at Zacks Research to a "hold" rating.
10/27
08:06 am
slgl
Sol-Gel Technologies (NASDAQ:SLGL) had its price target raised by analysts at HC Wainwright from $6.00 to $50.00. They now have a "buy" rating on the stock.
Low
Report
Sol-Gel Technologies (NASDAQ:SLGL) had its price target raised by analysts at HC Wainwright from $6.00 to $50.00. They now have a "buy" rating on the stock.
9/10
01:42 pm
slgl
Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight [Yahoo! Finance]
Neutral
Report
Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight [Yahoo! Finance]